StreetInsider.com News Articles

Form 4 Greenwich LifeSciences, For: Jul 27 Filed by: Patel Snehal

Wed, 29 Jul 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260729/26829804.html

Form 4 Greenwich LifeSciences, For: Jul 27 Filed by: Patel Snehal

Wed, 29 Jul 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260729/26829804.html

Form 4 Greenwich LifeSciences, For: Jul 23 Filed by: Patel Snehal

Mon, 27 Jul 2026 06:15:00 -0400

si-local-file:///var/storage/secattach/20260727/26815506.html

Form 4 Greenwich LifeSciences, For: Jul 23 Filed by: Patel Snehal

Mon, 27 Jul 2026 06:15:00 -0400

si-local-file:///var/storage/secattach/20260727/26815506.html

Greenwich LifeSciences wins UK approval to expand breast cancer trial

Wed, 22 Jul 2026 06:01:45 -0400

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that UK regulators have approved the expansion of its Phase III clinical trial, FLAMINGO-01, into the United Kingdom, adding potentially 5 to 10 sites to the approximately 170 to 180 already approved in the US and Europe.

The trial is evaluating GLSI-100, an immunotherapy candidate intended to prevent breast cancer recurrences in HER2-positive patients who have undergone surgery. Greenwich LifeSciences said it is collaborating with The Royal Marsden cancer center on the expansion, with discussions underway at academic sites in London, Cambridge, Edinburgh, Oxford, Manchester, Southampton, Cardiff, and other cities. The principal investigator at The

Greenwich LifeSciences wins UK approval to expand breast cancer trial

Wed, 22 Jul 2026 06:01:45 -0400

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

Wed, 22 Jul 2026 06:00:00 -0400

STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the regulatory approval to expand FLAMINGO-01 into the United Kingdom.

The Company's application to expand FLAMINGO-01 into the UK has been formally approved by UK regulators, thus adding potentially 5-10 geographically distributed UK sites to the approximately 170-180 approved sites in the US and Europe.

The Company is collaborating with The Royal Marsden,

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

Wed, 22 Jul 2026 06:00:00 -0400

The Company is collaborating with The Royal Marsden,

Greenwich LifeSciences (GLSI) PT Raised to $69 at H.C. Wainwright

Tue, 21 Jul 2026 12:31:31 -0400

H.C. Wainwright analyst Yi Chen raised the price target on Greenwich LifeSciences (NASDAQ: GLSI) to $69.00 (from $50.00) while maintaining a Buy rating.

Greenwich LifeSciences updates FLAMINGO-01 trial design and reports financials

Mon, 20 Jul 2026 06:01:40 -0400

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) provided clinical updates on its Phase III breast cancer immunotherapy trial, FLAMINGO-01, including regulatory-reviewed design changes and preliminary financial figures, according to a press release from the Stafford, Texas-based company.

The trial's Data Safety Monitoring Board met in May 2026 and recommended the study continue without modification. Following review by the U.S. Food and Drug Administration and the European Medicines Agency, the company said several planned protocol modifications have been implemented. These include expanding the maximum enrollment to 2,000 patients, combining all HLA types in the randomized arms, and adjusting the event thresholds for interim analyses

Greenwich LifeSciences updates FLAMINGO-01 trial design and reports financials

Mon, 20 Jul 2026 06:01:40 -0400

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

Mon, 20 Jul 2026 06:00:00 -0400

STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following clinical updates on FLAMINGO-01.

FLAMINGO-01 Data Safety Monitoring Board (DSMB)

The FLAMINGO-01 DSMB met in May 2026 and recommended the study continue as is without modification.

FLAMINGO-01 Steering Committee Clinical Strategy

On December 22, 2025, the company announced the following objectives:

"The Steering Committee

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

Mon, 20 Jul 2026 06:00:00 -0400

FLAMINGO-01 Data Safety Monitoring Board (DSMB)

The FLAMINGO-01 DSMB met in May 2026 and recommended the study continue as is without modification.

FLAMINGO-01 Steering Committee Clinical Strategy

On December 22, 2025, the company announced the following objectives:

"The Steering Committee

EMA approves combining HLA patient groups in Greenwich LifeSciences trial

Thu, 16 Jul 2026 07:31:07 -0400

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that the European Medicines Agency (EMA) has completed its review and will allow the combination of both HLA-A*02 and non-HLA-A*02 patients in the FLAMINGO-01 Phase III clinical trial in Europe.

The decision aligns European sites with a protocol already in place at U.S. sites, where the Food and Drug Administration previously reviewed and allowed the same change. All 170 to 180 clinical sites across the U.S. and Europe are now operating under the same protocol. The company said data can also be analyzed by individual HLA types.

Non-HLA-A*02 patients represent approximately 55% of the general population

EMA approves combining HLA patient groups in Greenwich LifeSciences trial

Thu, 16 Jul 2026 07:31:07 -0400

Non-HLA-A*02 patients represent approximately 55% of the general population

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

Thu, 16 Jul 2026 07:30:00 -0400

STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the combination of both HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 in Europe.

All European and US Sites to Combine All Patients Independent of HLA Type in the Randomized Arms of FLAMINGO-01

The Company previously announced that US clinical sites started enrolling both HLA-A*02 and non-HLA-A*02 patients in the same

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

Thu, 16 Jul 2026 07:30:00 -0400

All European and US Sites to Combine All Patients Independent of HLA Type in the Randomized Arms of FLAMINGO-01

The Company previously announced that US clinical sites started enrolling both HLA-A*02 and non-HLA-A*02 patients in the same

EMA clears commercially made GP2 for use in Greenwich LifeSciences trial

Thu, 09 Jul 2026 06:00:46 -0400

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) announced that the European Medicines Agency (EMA) has completed its review and approved the use of a commercially manufactured GP2 lot in the company's Phase III breast cancer trial, FLAMINGO-01.

The approval means all clinical sites in the United States and Europe — now numbering approximately 170 to 180, up from 160 — will use the same commercially manufactured GP2 lot. Shipments to European pharmacies are already under way, according to a company press release. Greenwich LifeSciences said it is separately seeking approval to use the same lot in the United Kingdom and Canada.

The commercial GP2

EMA clears commercially made GP2 for use in Greenwich LifeSciences trial

Thu, 09 Jul 2026 06:00:46 -0400

The commercial GP2

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

Thu, 09 Jul 2026 06:00:00 -0400

STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01 in Europe.

All European and US Sites to Treat Patients with Commercially Manufactured GP2

The Company previously announced that the first three commercial lots of GP2 active ingredient were manufactured in 2023 in an approved commercial facility, which could be used

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

Thu, 09 Jul 2026 06:00:00 -0400

All European and US Sites to Treat Patients with Commercially Manufactured GP2

The Company previously announced that the first three commercial lots of GP2 active ingredient were manufactured in 2023 in an approved commercial facility, which could be used

Form 10-Q Greenwich LifeSciences, For: Mar 31

Thu, 04 Jun 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260604/26601814.html

Form 10-Q Greenwich LifeSciences, For: Mar 31

Thu, 04 Jun 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260604/26601814.html

Form 10-K Greenwich LifeSciences, For: Dec 31

Mon, 01 Jun 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260601/26584764.html

Form 10-K Greenwich LifeSciences, For: Dec 31

Mon, 01 Jun 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260601/26584764.html